Hoosiers Work For Health is the Indiana chapter of a national initiative that unites health consumers, biopharmaceutical company employees, vendors, suppliers and other business and community partners to demonstrate how these diverse groups are vital to Indiana’s socioeconomic climate, and provide shared benefits and a better quality of life to all.
Specifically, the partnership includes local chambers of commerce and research centers, labor, businesses, patient advocacy organizations, provider groups and biopharmaceutical research companies that work together to improve America’s health care system and strengthen our economy.
The biopharmaceutical sector is the foundation of one of Indiana’s most dynamic innovation and business ecosystems. Not only does the industry invest heavily in the research and development of new treatments and cures, it also generates high quality jobs, powers economic output and exports for the U.S. economy and sustains a very large-scale supply chain.
Update
Read our statement of opposition on HR 3 and other drug pricing proposals.
Learn about the economic impact of HR 3 and drug pricing proposals in Indiana.
Supporting High Quality Jobs in Indiana
The innovative biopharmaceutical sector directly supported 25,723 jobs in Indiana in 2020. These jobs are often high-skill, high-wage professions.
The industry also supported another 104,641 jobs indirectly, for a total of about 130,364 jobs across the Indiana economy. These additional jobs are with vendors and suppliers such as construction companies and I.T. companies, and jobs generated by the sector’s employees such as day care centers and restaurants.
Indiana workers whose jobs were supported by the biopharmaceutical sector paid a total of $2.1 billion in personal taxes in 2020—$1.8 million in federal taxes and $242.7 million in state taxes.
Indiana's Economic Impact
In 2020, the biopharmaceutical sector supported $56.4 billion in economic output for the state of Indiana—including $37.3 billion generated directly by the sector, and another $19 billion through its vendors and suppliers and through the economic activity of its workforce.
vendor relationships
vendor spending
$1,084,286,653
Find Your
Elected Officials
Partners
For more information on Hoosiers Work For Health, please contact us at info@weworkforhealth.org.
Join
Media
Dr. Janelle A. Sabo currently leads clinical systems, supply and innovation within the Clinical Design, Delivery, and Analytics division, enabling clinical development from early discovery through commercialization. She helped develop Indiana's largest COVID-19 reference lab...
Dr. Janelle A. Sabo currently leads clinical systems, supply and innovation within the Clinical Design, Delivery, and Analytics division, enabling clinical development from early discovery through commercialization. She helped develop Indiana's largest COVID-19 reference lab and the state’s largest drive through testing facility. Along with Chris Otto, she assisted in building a lab design strategy and a supply chain management program that built the state’s capacity to almost 30,000 COVID-19 tests per day.
Chris is currently the Senior Director for Clinical Laboratory Sciences with over 25 years of experience with Eli Lilly and Company. Chris and Dr. Janelle Sabo helped develop Indiana's largest COVID-19 reference lab that helped the state almost immediately increase its...
Chris is currently the Senior Director for Clinical Laboratory Sciences with over 25 years of experience with Eli Lilly and Company. Chris and Dr. Janelle Sabo helped develop Indiana's largest COVID-19 reference lab that helped the state almost immediately increase its testing capacity from approximately 300 tests per day to 30,000 tests per day.
As Lilly develops facilities plans across the country and worldwide, D.R. includes the Government Affairs team in the planning process to help understand assets on the ground in high-impact locations and how a policy shift might change the economic metrics of a decision. He...
As Lilly develops facilities plans across the country and worldwide, D.R. includes the Government Affairs team in the planning process to help understand assets on the ground in high-impact locations and how a policy shift might change the economic metrics of a decision. He has a deep knowledge of the industry, and when Lilly engages policymakers at the state and federal level, D.R. is part of the team that walks them through the facilities, explains how the supply chain works and discusses how decisions made in legislative committee rooms and regulatory bodies impact Lilly in meaningful ways.
